- Home
- MASK vs EXEL Comparison
MASK vs EXEL Comparison
Compare MASK & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MASK
- EXEL
- Stock Information
- Founded
- MASK 2017
- EXEL 1994
- Country
- MASK China
- EXEL United States
- Employees
- MASK N/A
- EXEL N/A
- Industry
- MASK
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MASK
- EXEL Health Care
- Exchange
- MASK NYSE
- EXEL Nasdaq
- Market Cap
- MASK 38.3M
- EXEL 9.8B
- IPO Year
- MASK 2025
- EXEL 2000
- Fundamental
- Price
- MASK $3.70
- EXEL $36.98
- Analyst Decision
- MASK
- EXEL Buy
- Analyst Count
- MASK 0
- EXEL 18
- Target Price
- MASK N/A
- EXEL $37.59
- AVG Volume (30 Days)
- MASK 32.3K
- EXEL 2.3M
- Earning Date
- MASK 01-01-0001
- EXEL 05-13-2025
- Dividend Yield
- MASK N/A
- EXEL N/A
- EPS Growth
- MASK 12.16
- EXEL 170.77
- EPS
- MASK 0.19
- EXEL 1.76
- Revenue
- MASK $4,718,055.00
- EXEL $2,168,701,000.00
- Revenue This Year
- MASK N/A
- EXEL $5.78
- Revenue Next Year
- MASK N/A
- EXEL $10.94
- P/E Ratio
- MASK $17.79
- EXEL $21.01
- Revenue Growth
- MASK 7.89
- EXEL 18.50
- 52 Week Low
- MASK $2.50
- EXEL $20.14
- 52 Week High
- MASK $4.19
- EXEL $40.26
- Technical
- Relative Strength Index (RSI)
- MASK N/A
- EXEL 49.13
- Support Level
- MASK N/A
- EXEL $34.90
- Resistance Level
- MASK N/A
- EXEL $37.39
- Average True Range (ATR)
- MASK 0.00
- EXEL 1.23
- MACD
- MASK 0.00
- EXEL -0.19
- Stochastic Oscillator
- MASK 0.00
- EXEL 38.81
About MASK 3 E NETWORK TECHNOLOGY GROUP LTD
3 E Network Technology Group Ltd is a business-to-business (B2B) information technology (IT) business solutions provider. It focuses on integrated software and hardware solutions in the property management and exhibition services spaces and expanded software solutions offering to a variety of industries and sectors, including food establishments, real estate, exhibition & conferencing, and clean energy utilities. The business includes two main portfolios, namely the software development portfolio and exhibition and conference portfolio. Maximum revenue is generated from the software development portfolio.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.